Historically, approaches to treating lung cancer included surgery, radiation, and chemotherapy. The past decade ushered in a new era of treatments with targeted therapy and immunotherapy. Now, we are seeing the emergence of another class of lung cancer treatments called antibody-drug conjugates (ADCs), that are a combination of targeted therapy and chemotherapy.
ADCs act like a “smart chemotherapy” that aim to deliver the drug compound directly to cancer cells, reducing harm to healthy tissue.
As part of LUNGevity’s International Lung Cancer Survivorship Conference last September, we hosted an educational session about ADCs with Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center and Amy Moore, PhD, of LUNGevity Foundation. In the video below, Dr. Levy explains what ADCs are and why they are exciting for the lung cancer community.
Many studies are underway to evaluate the use of ADCs in treating different types of lung cancer.
Sign up here to be notified when registration opens for the 2025 International Lung Cancer Survivorship Conference.